Brief: Mabion Estimates Capex At About 90-100 Mln Zlotys In 2023-24 under new strategy

Mabion SA

18/04/2023 07:24

April 18 (Reuters) - Mabion SA  MABP.WA :
    * ADOPTS STRATEGY FOR 2023-2027
    * UNDER STRATEGY ESTIMATES CAPEX AT ABOUT 90-100 MILLION ZLOTYS IN 2023-24 
    * CAPEX FOR 2023-24 WILL BE FINANCED FROM FUNDS GENERATED IN THE COMPANY AND
FROM
THE EBRD LOAN
    * CAPEX FOR 2023-24 WILL BE USED FOR INVESTMENTS IN MODERNIZATION OF THE
MABION I
FACILITY AND INVESTMENTS IN RETROFITTING OF THE FACILITY AND NEW PROJECTS
    * CAPEX FOR 2025-27 DEPENDS ON THE DECISION ON START OF CONSTRUCTION OF
MABION II
FACILITY, WHICH WILL REQUIRE OBTAINING EXTERNAL FINANCING
    * ESTIMATES ANNUAL REVENUE POTENTIAL IN 2023-27 AT 150-200 MILLION ZLOTYS
    * ESTIMATES EBITDA MARGIN AT ABOUT 25% IN 2023
    * ESTIMATES EBITDA MARGIN AT 20%-30% IN 2024-27
    * COMPANY AIMS TO BECOME FULLY INTEGRATED BIO-PROFILE CDMO PROVIDING A WIDE
RANGE
OF SERVICES FOR SMALL AND MEDIUM PROJECTS (FROM THE EARLY STAGE OF DISCOVERY
TILL COMMERCIAL MANUFACTURE) FOR CUSTOMERS ON DIFFERENT STAGES OF DEVELOPMENT
    * PLANS TO CHANGE COMPANY PROFILE FROM PRODUCT (OWN PRODUCTS) TO SERVICE
(CONTRACTUAL SERVICES)
    * COMPANY STOPS WORKING ON BUILDING ITS OWN PRODUCT PORTFOLIO PRODUCTS IN
TERMS OF
PROJECTS DENOSUMAB, OMALIZUMAB AND MABIONMS
    * PLANS INVESTMENTS IN INCREASING THE PRODUCTION AND ANALYTICAL CAPACITY IN
TERMS
OF CDMO AND INCREASING OPERATIONAL FLEXIBILITY - IN THE FIRST STAGE, THE
MODERNISATION OF MABION I FACILITY, AND THEN THE START OF INVESTMENT IN MABION
II FACILITY
    * THE PROCESS OF ACQUIRING A STRATEGIC INVESTOR REMAINS OPEN TO POTENTIAL
TALKS
WITH POSSIBLE PARTNERS, HOWEVER, THE TRANSFORMATION TOWARDS CDMO BECOMES A
PRIORITY

        
 Source text for Eikon:  urn:newsml:reuters.com:*:nEM34t1xsa
 Further company coverage:  MABP.WA  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))